首页> 外文期刊>Research and practice in thrombosis and haemostasis. >A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study
【24h】

A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study

机译:一种混合方法研究,评估患者设计的工具,以减少癌症相关血栓形成的危害:授权研究

获取原文
           

摘要

Introduction Venous thromboembolism (VTE) is a common and serious complication of systemic anticancer therapies. Delays in presentation increase risk of death or long-term morbidity. Background A patient charity developed an information video for patients receiving systemic anticancer therapy including what to do if they developed symptoms of VTE. This was introduced into clinical practice in a regional cancer center and its impact compared with a district general hospital where the video was not used. Methods A mixed-methods approach was used, comprising clinical audit data, patient surveys, and key informant interviews. The time between development of VTE symptoms and seeking medical evaluation was routinely recorded on patients attending a regional cancer-associated thrombosis service with systemic anticancer therapy–provoked VTE. The video was then embedded into clinical practice at the regional cancer center for 3?months. The primary outcome was the difference in time to presentation with VTE symptoms, between patients attending the regional cancer center and the district general hospital (which acted as control). Other outcomes included impact on radiology resources, patient knowledge, and perspectives of chemotherapy nurses. Results Addition of the video was associated with a lower mean time to presentation from 8.9 to 2.9?days (0.33 hazard ratio; 95% confidence interval, 4.5-7.4; P ?.0001). This may reflect greater awareness of VTE, resulting in earlier clinical presentation when they developed attributable symptoms. Conclusion The video was associated with reduced delays in diagnosis of systemic anticancer therapy–associated VTE by 6?days, thereby reducing long-term complications.
机译:引言静脉血栓栓塞(VTE)是系统性抗癌疗法的常见和严重并发症。延迟介绍增加了死亡或长期发病的风险。背景技术患者慈善机构为接受全身抗癌治疗的患者开发了一种信息视频,包括如果它们在vteb中发展症状。将其引入区域癌症中心的临床实践及其影响与未使用视频的地区综合医院相比。方法使用混合方法方法,包括临床审计数据,患者调查和关键信息面试。常规记录VTE症状和寻求医学评估的患者患者的发展时间,并在出席具有全身抗癌治疗激发VTE的区域癌症相关血栓形成服务的患者中记录了患者。然后将该视频嵌入到区域癌症中心的临床实践中3?几个月。主要结果是在参加区域癌症中心和地区综合医院的患者之间与VTE症状呈现患者的时间差异,(担任控制)。其他结果包括对放射学资源,患者知识和化疗护士的观点的影响。结果增加了视频的增加与8.9至2.9?天(0.33危险比; 95%置信区间,4.5-7.4; P <。0001)。这可能反映了对VTE的更大意识,导致在开发可归因的症状时早期的临床表现。结论该视频与诊断系统抗癌治疗相关VTE的延迟减少6?天,从而减少了长期并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号